Aytu Biopharma Inc (AYTU) Stock Price, Quote & News

Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 720 437 6580

Website: aytubio.com

Address:

Denver Corporate Center III, Suite 920 7900 East Union Avenue, Denver, United States

Merlintrader May. 8 at 7:50 PM

$CING Cingulate ( $CING ) vs Aytu BioPharma ( $AYTU ): What a Commercial ADHD Peer Can — and Cannot — Tell Us Before CING’s May 31 PDUFA https://www.merlintrader.com/cingulate-vs-aytu-biopharma-may2026-comparison/

0 · Reply

SuperGreenToday May. 8 at 3:24 AM

$AYTU

0 · Reply

Alain_Simard May. 7 at 6:36 PM

$AYTU they are reporting earnings on the 13??? Sounds prophetic to me!!! lol

0 · Reply

Alain_Simard May. 5 at 7:29 PM

$AYTU when is this 💩 reporting? Should be coming up soon…

0 · Reply

bullsnhorns2 Apr. 30 at 3:18 AM

$AYTU wooooow hadnt seen this stock in years just came to check it out... i made fkin BANK with then whole heal light sht!

0 · Reply

brucino Apr. 28 at 2:06 PM

$CXAI $GPRO $EYPT $DOMH $AYTU hot !!!💣🚀💥💰💰

0 · Reply

brucino Apr. 20 at 6:59 AM

$GPRO 💣🚀🛰️ ticker of the day $GPRO $DOMH $EYPT $AYTU $CXAI Let'go !!!!💣🚀

0 · Reply

Fibonacci5 Apr. 10 at 11:37 AM

$AYTU this is getting bot out.

1 · Reply

pamplon Apr. 2 at 10:45 PM

$AYTU This is really good news https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&ref=319930169&type=PDF&symbol=AYTU&cdn=f2c683ce4fe38b388f07f88e95c50879&companyName=Aytu+BioPharma%2C+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-04-02

3 · Reply

inv1ncible Mar. 23 at 7:08 PM

$AYTU trash ceo and stock

0 · Reply

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

2026-02-03T21:50:30.000Z - 3 months ago

Aytu BioPharma reports Q2 EPS ($1.05) vs. 13c last year

Feb 3, 2026, 4:30 PM EST - 3 months ago

Aytu BioPharma Earnings Call Transcript: Q2 2026

Feb 3, 2026, 4:05 PM EST - 3 months ago

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Jan 27, 2026, 4:05 PM EST - 3 months ago

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Jan 20, 2026, 4:05 PM EST - 3 months ago

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Jan 20, 2026, 11:00 AM EST - 3 months ago

Aytu BioPharma Transcript: Investor Day 2026

2026-01-20T14:20:18.000Z - 3 months ago

Aytu BioPharma announces nationwide commercial launch of EXXUA

Jan 15, 2026, 5:00 PM EST - 4 months ago

Aytu BioPharma Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 13, 2026, 4:15 PM EST - 4 months ago

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Jan 12, 2026, 8:00 AM EST - 4 months ago

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Dec 18, 2025, 9:00 AM EST - 5 months ago

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

2025-12-15T14:20:55.000Z - 5 months ago

Aytu BioPharma announces commercial availability of EXXUA tablets

Dec 15, 2025, 9:00 AM EST - 5 months ago

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Nov 24, 2025, 4:05 PM EST - 5 months ago

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 13, 2025, 4:30 PM EST - 6 months ago

Aytu BioPharma Earnings Call Transcript: Q1 2026

Nov 13, 2025, 4:05 PM EST - 6 months ago

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 5, 2025, 4:05 PM EST - 6 months ago

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

2025-10-28T13:20:53.000Z - 6 months ago

Aytu BioPharma announces patent term extension for EXXUA

Oct 28, 2025, 9:00 AM EDT - 6 months ago

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 22, 2025, 2:30 PM EDT - 7 months ago

Aytu BioPharma Transcript: Planet MicroCap Showcase: TORONTO 2025

Oct 10, 2025, 9:00 AM EDT - 7 months ago

Aytu BioPharma to Present at Upcoming October 2025 Conferences

2025-10-01T14:40:36.000Z - 7 months ago

Aytu BioPharma management to meet with Lake Street

Sep 30, 2025, 2:45 PM EDT - 7 months ago

Aytu BioPharma Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 25, 2025, 2:00 PM EDT - 8 months ago

Aytu BioPharma Transcript: MicroCap Rodeo Fall Conference

2025-09-25T12:05:29.000Z - 8 months ago

Aytu BioPharma price target lowered to $7 from $9 at Maxim

Sep 24, 2025, 4:15 PM EDT - 8 months ago

Aytu BioPharma to Present at Upcoming September 2025 Conferences

2025-09-24T16:16:41.000Z - 8 months ago

Aytu BioPharma price target lowered to $7 from $9 at Maxim

Sep 23, 2025, 4:30 PM EDT - 8 months ago

Aytu BioPharma Earnings Call Transcript: Q4 2025

Sep 23, 2025, 4:05 PM EDT - 8 months ago

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 16, 2025, 4:05 PM EDT - 8 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

2025-07-08T17:45:24.000Z - 10 months ago

Aytu BioPharma management to meet with Maxim

2025-07-01T12:55:58.000Z - 11 months ago

Aytu BioPharma initiated with a Buy at Lake Street

2025-06-30T09:20:10.000Z - 11 months ago

Aytu BioPharma initiated with a Buy at Ascendiant

2025-06-25T12:30:52.000Z - 11 months ago

Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs

Jun 25, 2025, 8:00 AM EDT - 11 months ago

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

2025-06-23T17:53:35.000Z - 11 months ago

Aytu BioPharma expands, extends lending agreement with Eclipse

Jun 23, 2025, 8:00 AM EDT - 11 months ago

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 11, 2025, 4:30 PM EDT - 11 months ago

Aytu BioPharma Transcript: Investor Update

Jun 9, 2025, 4:30 PM EDT - 11 months ago

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

2025-06-06T12:45:21.000Z - 1 year ago

Aytu BioPharma 9.6M share Secondary priced at $1.50

2025-06-06T12:15:35.000Z - 1 year ago

Aytu BioPharma enters exclusive agreement with Fabre-Kramer Pharmaceuticals

2025-06-06T12:15:25.000Z - 1 year ago

Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering

2025-06-06T12:15:20.000Z - 1 year ago

Aytu BioPharma announces exclusive commercialization agreement for Exxua

Jun 6, 2025, 8:01 AM EDT - 1 year ago

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

2025-06-02T21:20:08.000Z - 1 year ago

Aytu BioPharma files to sell 6.74M shares of common stock

May 14, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q3 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 7, 2025, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

2025-04-14T22:15:09.000Z - 1 year ago

Aytu BioPharma’s treatment of Marfan syndrome receives FDA orphan designation

Feb 12, 2025, 4:03 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 12, 2025, 4:00 PM EST - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q2 2025

Feb 5, 2025, 5:50 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Jan 6, 2025, 9:00 AM EST - 1 year ago

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 3, 2024, 11:45 PM EST - 1 year ago

Aytu BioPharma Disclosure Notification

Nov 22, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 13, 2024, 4:30 PM EST - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q1 2025

Nov 13, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 6, 2024, 5:20 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Oct 16, 2024, 2:00 PM EDT - 1 year ago

Aytu BioPharma Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 14, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

2024-10-01T12:55:27.000Z - 1 year ago

Aytu BioPharma enters exclusive commercialization agreement with Lupin

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Sep 26, 2024, 4:30 PM EDT - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q4 2024

Sep 26, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 19, 2024, 5:30 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aug 15, 2024, 12:15 PM EDT - 1 year ago

Aytu BioPharma Transcript: Sidoti Micro-Cap Virtual Conference

Aug 8, 2024, 5:20 PM EDT - 1 year ago

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

May 15, 2024, 4:30 PM EDT - 2 years ago

Aytu BioPharma Earnings Call Transcript: Q3 2024

May 15, 2024, 4:05 PM EDT - 2 years ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

May 8, 2024, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Apr 4, 2024, 4:40 PM EDT - 2 years ago

Aytu BioPharma Transcript: Emerging Growth Conference

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Feb 14, 2024, 4:30 PM EST - 2 years ago

Aytu BioPharma Earnings Call Transcript: Q2 2024

Feb 14, 2024, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Feb 7, 2024, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Feb 1, 2024, 11:45 AM EST - 2 years ago

Aytu BioPharma Transcript: Lytham Partners 2024 Select Conference

Jan 23, 2024, 9:00 AM EST - 2 years ago

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Nov 30, 2023, 8:00 AM EST - 2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Aytu BioPharma Earnings Call Transcript: Q1 2024

Nov 14, 2023, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Nov 8, 2023, 8:30 AM EST - 2 years ago

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Nov 7, 2023, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Oct 9, 2023, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Merlintrader May. 8 at 7:50 PM

0 · Reply

SuperGreenToday May. 8 at 3:24 AM

$AYTU

0 · Reply

Alain_Simard May. 7 at 6:36 PM

$AYTU they are reporting earnings on the 13??? Sounds prophetic to me!!! lol

0 · Reply

Alain_Simard May. 5 at 7:29 PM

$AYTU when is this 💩 reporting? Should be coming up soon…

0 · Reply

bullsnhorns2 Apr. 30 at 3:18 AM

$AYTU wooooow hadnt seen this stock in years just came to check it out... i made fkin BANK with then whole heal light sht!

0 · Reply

brucino Apr. 28 at 2:06 PM

$CXAI $GPRO $EYPT $DOMH $AYTU hot !!!💣🚀💥💰💰

0 · Reply

brucino Apr. 20 at 6:59 AM

$GPRO 💣🚀🛰️ ticker of the day $GPRO $DOMH $EYPT $AYTU $CXAI Let'go !!!!💣🚀

0 · Reply

Fibonacci5 Apr. 10 at 11:37 AM

$AYTU this is getting bot out.

1 · Reply

pamplon Apr. 2 at 10:45 PM

3 · Reply

inv1ncible Mar. 23 at 7:08 PM

$AYTU trash ceo and stock

0 · Reply

inv1ncible Mar. 20 at 4:48 AM

$AYTU

0 · Reply

Lucas76 Mar. 19 at 9:34 PM

$AYTU Now that's impressive:

0 · Reply

termoil Mar. 18 at 3:58 PM

$AYTU If the board decides to sell then what would be a fair price per share?

1 · Reply

YourObscureCEOforLife Mar. 17 at 8:51 PM

$AYTU

0 · Reply

Alain_Simard Mar. 13 at 1:56 PM

$AYTU the only thing that $AYTU has going for it is that it doesn’t have any Iran exposure

0 · Reply

Love_To_Learn Mar. 11 at 8:47 PM

$CDXS 1.8 key now old beloved sending code now also main 1.8 key creator $AYTU executing !

1 · Reply

mfoxx Mar. 11 at 5:29 PM

$AYTU when delist?

0 · Reply

Love_To_Learn Mar. 11 at 1:09 PM

$AYTU $SIDU $BDRX MAKING CHANGES TO ALL 3 OF U

0 · Reply

MadryKielbasa Mar. 9 at 4:54 PM

$AYTU

1 · Reply

BillionerOfKing Feb. 27 at 11:55 PM

$AYTU Current Stock Price: $2.57

0 · Reply

OfficialStocktwitsUser Feb. 26 at 7:15 PM

$AYTU RSI: 61.90, MACD: -0.0554 Vol: 0.16, MA20: 2.36, MA50: 2.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Pocahonta Feb. 25 at 9:51 PM

$AYTU Dishbrow ain’t in jail yet? Still Trading and deceiving Investors? Where are the FEDS???

0 · Reply

Market Cap	27.48M
Revenue (ttm)	66.38M
Net Income (ttm)	-13.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.43%
Debt to Equity Ratio	1.47

Volume	7,700
Avg Vol	42,464
Day's Range	N/A - N/A
Shares Out	10.73M
Stochastic %K	0%
Beta	0.28
Analysts	Sell
Price Target	$9.67